However, approximately 15% of patients with N+ and HR+/HER2- BC receiving endocrine therapy develop tumor recurrence within 5 years of initiating treatment, indicating a requirement for developing novel treatment strategies in this patient subset (5). The gene discussed is ERBB2; the disease is breast cancer.